Open AccessP062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
Author(s) -
Fedorova Liudmila,
Lepik Kirill,
Mikhailova Natalia,
Kondakova Elena,
Komarova Yaroslava,
Kotselyabina Polina,
Borzenkova Evgenia,
Baykov Vadim,
Moiseev Ivan,
Kulagin Alexander
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890816.89900.95
Subject(s) - medicine , nivolumab , refractory (planetary science) , regimen , adverse effect , dosing , progression free survival , cohort , lymphoma , gastroenterology , oncology , chemotherapy , surgery , cancer , immunotherapy , physics , astrobiology